A Mab A Case Study In Bioprocess Development -

The development of is not a linear path but a complex optimization problem spanning molecular biology, chemical engineering, and analytical chemistry. This case study of Mab-X demonstrates that success requires not just high titers, but a holistic understanding of how each unit operation affects product quality. With the advent of continuous bioprocessing, machine learning-driven process control, and novel affinity ligands, the future of Mab manufacturing promises cheaper, faster, and more robust processes. Yet the fundamental principles revealed here—clone selection, impurity mapping, scale-up fidelity, and formulation science—will remain the bedrock of bioprocess development for decades to come.

The tech transfer succeeded after three engineering runs, with yield within 95–102% of pilot scale.

Final titer = 4.2 g/L, viability >75% at harvest. A 2.5-fold improvement over initial process.